Promising Potential and Strategic Pipeline: A Buy Recommendation for Nurix Therapeutics
I'm PortAI, I can summarize articles.
Robert Burns has issued a Buy recommendation for Nurix Therapeutics, citing promising Phase 1a results for NX-1607, a CBL-B inhibitor, presented at the ESMO meeting. The drug shows favorable safety and potential in combination therapies. Upcoming clinical data catalysts enhance optimism for the pipeline, with a firm valuation of approximately $2.8 billion and a 12-month price target of $33 per share. Needham also maintains a Buy rating with a $27.00 price target, though risks in clinical trials and market challenges remain.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments